23 completed, 9 recruiting, 2 active not recruiting, 2 not yet recruiting. 38 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 23, Recruiting 9, Active not recruiting 2, Not yet recruiting 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 3, Recruiting 2, Active not recruiting 1, Unknown 1 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS LOU064, Placebo - Hidradenitis Suppurativa | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-10-15 | 2026-10-16 |
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa Soquelitinib - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | 25 | 2026-09-17 | 2026-10-15 |
| Biological, Radiographic and Clinical Evaluation of Various Inter-Visit Root Canal Dressings in Retreatment Cases Calcium Silicate Intracanal Medication, Calcium Hydroxide Slurry mixed with Sodium Hypochlorite Intracanal Medication, Calcium Hydroxide (Ca(OH)2) Intracanal Medication - Intervention Studies, ASA Physical Status I | Phase 1 | Recruiting | Ain Shams University | 60 | 2026-06-01 | 2026-06-12 |
| FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study Fecal microbiota transplantation (FMT) - Hidradenitis Suppurativa (HS), Fecal Microbiota Transplantation (FMT) | Phase 1 | Not yet recruiting | University Hospital, Clermont-Ferrand | 24 | 2026-06-01 | 2026-06-25 |
| Abdominal aBscess Catheter Sclerotherapy (ABCS) Catheter Sclerotherapy - Abdominal Abscess | Phase 1 / Phase 2 | Active not recruiting | University of Alabama at Birmingham | 60 | 2025-12-21 | 2026-09-24 |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | UCB Biopharma SRL | 20 | 2025-11-05 | 2026-09-18 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa Ruxolitinib Cream - Hidradenitis Suppurativa | Phase 1 | Recruiting | Incyte Corporation | 24 | 2025-11-03 | 2026-10-09 |
| 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) AviClear Lase Treatment, Sham (No Treatment) - Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Wynn Medical Center | 30 | 2025-09-15 | 2025-09-17 |
| Neutralizing Interferon Type 1 in Hidradenitis Suppurativa Plasma with neutralizing autoantibodies to Type I Interferons - Hidradenitis Suppurativa (HS) | Phase 1 | Not yet recruiting | Centre Hospitalier Universitaire de Besancon | 6 | 2025-09-01 | 2025-07-16 |
| A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa LT-002-158 Tablets - Hidradenitis Suppurativa (HS) | Phase 1 / Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 12 | 2025-07-08 | 2026-08-27 |
| A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients QLS12010, Placebo - Atopic Dermatitis, Hidradenitis Suppurativa (HS) | Phase 1 | Recruiting | Shanghai Qilu Pharmaceutical Research and Development Center LTD | 102 | 2025-03-31 | 2025-07-31 |
| Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. HB0043 - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Recruiting | Shanghai Huaota Biopharmaceutical Co., Ltd. | 15 | 2025-03-19 | 2026-01-07 |
| Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa SBT777101 - Hidradenitis Suppurativa | Phase 1 | Active not recruiting | Sonoma Biotherapeutics, Inc. | 24 | 2024-10-09 | 2026-02-20 |
| A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers LT-002-158/Placebo oral tablet(s) - Healthy Volunteer, Hidradenitis Suppurativa | Phase 1 | Completed | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 150 | 2024-06-13 | 2026-08-27 |
| Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Injectable suspension of allogeneic adult mesenchymal stem cells, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Unknown | Andalusian Network for Design and Translation of Advanced Therapies | 30 | 2022-10-26 | 2023-07-07 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
| Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa AT193 - Hidradenitis Suppurativa | Phase 1 | Completed | Azora Therapeutics Australia Pty Ltd | 49 | 2021-11-23 | 2024-03-15 |
| A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. RGRN-305, Placebo - Hidradenitis Suppurativa | Phase 1 | Completed | Aarhus University Hospital | 15 | 2021-09-01 | 2023-01-31 |
| Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) BDB-001 Injection, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 50 | 2021-06-24 | 2024-03-26 |
| Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa AMP-001 Low Dose, AMP-001 Medium Dose, AMP-001 High Dose - Hidradenitis Suppurativa | Phase 1 | Withdrawn | IntegoGen, LLC | 2021-04-01 | 2021-09-08 |
Showing 20 of 38. Sign in to see all of them.
Hidradenitis Suppurativa (24) · Cellulitis (7) · Arthritis, Psoriatic (3) · Arthritis, Rheumatoid (3) · Dermatitis, Atopic (3) · Abscess (2) · Acne Vulgaris (2) · Arthritis, Juvenile (2) · Colitis, Ulcerative (2) · Crohn Disease (2) · Encephalitis (2) · HIV Infections (2) · Infections (2) · Spondylitis, Ankylosing (2) · Staphylococcal Skin Infections (2)
Infections (36) · Skin Diseases, Infectious (31) · Skin and Connective Tissue Diseases (31) · Skin Diseases (27) · Bacterial Infections (26) · Bacterial Infections and Mycoses (26) · Skin Diseases, Bacterial (26) · Sweat Gland Diseases (24) · Hidradenitis (23) · Connective Tissue Diseases (10) · Inflammation (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Immune System Diseases (8)
Leucovorin (2) · Pyrimethamine (2) · ceftobiprole (2) · Adalimumab (1) · Azithromycin (1) · BDB001 (1) · Calcium Hydroxide (1) · Cefadroxil (1) · Cephalexin (1) · Fecal Microbiota Transplantation (1) · Granulocyte Colony-Stimulating Factor (1) · High-Energy Shock Waves (1) · Hydroxychloroquine (1) · Isotretinoin (1) · Methylene Blue (1)
GlaxoSmithKline (3) · Basilea Pharmaceutica (2) · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (2) · Aarhus University Hospital (1) · Ain Shams University (1) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Azora Therapeutics Australia Pty Ltd (1) · CSL Behring (1) · Centre Hospitalier Universitaire de Besancon (1) · Corvus Pharmaceuticals, Inc. (1) · Elena Gonzalez Brant, MD (1) · Fresenius Kabi SwissBioSim GmbH (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Incyte Corporation (1) · Institute of Child Health (1)
United States (18) · China (5) · Spain (3) · Australia (2) · Denmark (2) · France (2) · Germany (2) · Argentina (1) · Canada (1) · Egypt (1) · Mexico (1) · Norway (1) · Switzerland (1) · United Kingdom (1)
Adam Jaffe, Dr (1) · Andrew Haynes, MD (1) · Ashwani K Sharma, MD (1) · Ashwin Gollerkeri, MD (1) · B Luft (1) · Baoxi Wang, Master (1) · Bruce Strober, MD, PhD (1) · Elena M Gonzalez Brant, MD (1) · Ethel C. Feleder, MD (1) · Isin Sinem Bagci, MD (1) · Joseph Arron, MD PhD (1)
PMID 18492739, PMID 31604104, PMID 35262901, PMID 37464107, PMID 37957373, PMID 37961683, PMID 38055242, PMID 38316055, PMID 38414658, PMID 38501946, PMID 40055981
2018 (1), 2025 (1)